First Trust Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

First Trust Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-169,004	Closed	-$17.4M	–	2546
2023 Q2	$17.4M	Sell	169,004 -123,940	-42%	-$13.1M	0.02%	811
2023 Q1	$32M	Sell	292,944 -19,206	-6%	-$2.12M	0.04%	559
2022 Q4	$35.5M	Sell	312,150 -80,060	-20%	-$6.65M	0.04%	523
2022 Q3	$24.3M	Buy	392,210 +124,767	+47%	+$8.72M	0.03%	617
2022 Q2	$21.3M	Sell	267,443 -372,228	-58%	-$35.2M	0.03%	677
2022 Q1	$67.3M	Buy	639,671 +47,575	+8%	+$4.64M	0.07%	403
2021 Q4	$63.8M	Sell	592,096 -102,378	-15%	-$11.2M	0.06%	422
2021 Q3	$76.1M	Buy	694,474 +60,288	+10%	+$6.26M	0.08%	313
2021 Q2	$59.4M	Sell	634,186 -6,767	-1%	-$623K	0.06%	420
2021 Q1	$59M	Buy	640,953 +107,339	+20%	+$9.06M	0.07%	394
2020 Q4	$39M	Sell	533,614 -4,048	-0.8%	-$301K	0.05%	468
2020 Q3	$41.8M	Sell	537,662 -199,805	-27%	-$13.7M	0.07%	386
2020 Q2	$41M	Sell	737,467 -431,990	-37%	-$18.5M	0.07%	391
2020 Q1	$34.6M	Buy	1,169,457 +159,984	+16%	+$5.41M	0.08%	400
2019 Q4	$36.5M	Buy	1,009,473 +471,687	+88%	+$14.5M	0.06%	453
2019 Q3	$14.6M	Buy	537,786 +318,316	+145%	+$8.23M	0.03%	698
2019 Q2	$5.28M	Sell	219,470 -33,538	-13%	-$851K	0.01%	1043
2019 Q1	$6.69M	Buy	253,008 +50,265	+25%	+$1.19M	0.01%	904
2018 Q4	$3.96M	Buy	202,743 +3,052	+2%	+$59.8K	0.01%	1082
2018 Q3	$3.91M	Buy	199,691 +114,205	+134%	+$2.17M	0.01%	1279
2018 Q2	$1.42M	Sell	85,486 -51,231	-37%	-$781K	﹤0.01%	1791
2018 Q1	$1.94M	Buy	136,717 +89,534	+190%	+$1.32M	﹤0.01%	1491
2017 Q4	$689K	Buy	+47,183	New	+$663K	﹤0.01%	1990
2017 Q3	–	Sell	-14,139	Closed	-$168K	–	2510
2017 Q2	$168K	Sell	14,139 -41,535	-75%	-$517K	﹤0.01%	2310
2017 Q1	$823K	Sell	55,674 -27,938	-33%	-$452K	﹤0.01%	1920
2016 Q4	$1.35M	Buy	83,612 +54,827	+190%	+$994K	﹤0.01%	1685
2016 Q3	$522K	Buy	+28,785	New	+$562K	﹤0.01%	1986

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

First Trust Advisors's HZNP Position: Q3 2023 in Review

First Trust Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2023, closing a stake of 169,004 shares — an estimated $17.4M sold.

First Trust Advisors first reported a position in HZNP in Q3 2016 and held it in 27 quarters. The position peaked at $76.1M in Q3 2021. 485 funds tracked by Wall St. Rank hold HZNP as of Q3 2023.

First Trust Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2023 after selling out during the quarter.
First Trust Advisors sold 169,004 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2023, an estimated $17.4M.
First Trust Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2016 and held it in 27 quarters.
First Trust Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $76.1M in Q3 2021.
485 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2023.

Based on First Trust Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.